Forthcoming proposals from the European Commission on reforming the EU’s pharmaceutical legislation “should not mainstream” fast-track regulatory approvals and should limit the use of conditional marketing authorization, the European Social Insurance Platform (ESIP) and the Medicine Evaluation Committee (MEDEV) have warned.
The two groups also want to see amendments to the legislation that would improve access to medicines by boosting competition,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?